Skip to content
HowShorted

Avidity Biosciences, Inc. short interest in 2021

In 2021, Avidity Biosciences, Inc.'s disclosed short interest ran from 8.46% of shares outstanding on 15 Jan 2021 to 8.43% on 31 Dec 2021, a change of -0.03 percentage points. The year's high was 17.52% on 14 May 2021 and its low 7.84% on 29 Jan 2021, averaging 13.47% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 50.34 days on 28 May 2021. Full history: Avidity Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Avidity Biosciences, Inc. in 2021

2021 in figures

Start of year
8.46% (15 Jan 2021)
End of year
8.43% (31 Dec 2021)
Change
-0.03 pp
High
17.52% (14 May 2021)
Low
7.84% (29 Jan 2021)
Average
13.47%
Highest days to cover
50.34 (28 May 2021)
SEC filings marked
9

Every report in 2021

Avidity Biosciences, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20218.46%19.02
29 Jan 20217.84%11.57
12 Feb 20218.51%15.03
26 Feb 20219.72%7.06
15 Mar 202111.87%12.1610-K filed, results (8-K)
31 Mar 202115.49%11.52
15 Apr 202116.96%21.10
30 Apr 202117.32%34.36
14 May 202117.52%30.5710-Q filed, results (8-K)
28 May 202117.44%50.34
15 Jun 202117.02%34.59
30 Jun 202116.29%17.76
15 Jul 202116.12%35.09
30 Jul 202116.10%31.34
13 Aug 202116.70%13.46results (8-K), 10-Q filed, results (8-K)
31 Aug 202117.30%26.11
15 Sep 202114.42%7.02
30 Sep 202114.97%13.79
15 Oct 202113.93%27.64
29 Oct 202111.34%37.91
15 Nov 202110.37%29.4910-Q filed, results (8-K)
30 Nov 202110.02%15.40
15 Dec 20219.08%13.82
31 Dec 20218.43%17.59

See also: Avidity Biosciences, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.